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The induction of antigen-specific tolerance is critical for the pre-
vention of autoimmunity and maintenance of immune tolerance.
In addition to their classical role as sentinels of the immune-
response-inducing T cell reactivity, dendritic cells (DCs) play an
important role in maintaining peripheral tolerance through the
inductionactivation of regulatory T cells (Tr). The possibility to
generate tolerogenic DCs opens new therapeutic perspectives in
autoimmuneinflammatory diseases. Therefore, the characteriza-
tion of the endogenous factors that contribute to the development
of tolerogenic DCs is highly relevant. In this study, we report on the
use of the known immunosuppressive neuropeptide, the vasoac-
tive intestinal peptide, as a new approach to induce tolerogenic
DCs with capacity to generate Tr cells, to restore tolerance in vivo,
and to reduce the progression of rheumatoid arthritis and exper-
imental autoimmune encephalomyelitis.
autoimmunity  regulatory T cell  tolerance
The immune system is faced with the daunting job of protectingthe host from an array of pathogens, while maintaining toler-
ance to self-antigens (Ags). The induction of Ag-specific tolerance
is essential to maintain immune homeostasis, to control autoreac-
tive T cells, preventing the onset of autoimmune diseases, and to
achieve tolerance toward transplants. Both thymic and peripheral
mechanisms account for the ability of the immune system to induce
tolerance. Attention has been focused recently on induction of
active suppression by regulatory T cells (Tr) (1), and dendritic cells
(DCs) have been shown to contribute to T cell tolerance (2, 3). The
maturationactivation state of DCs might be the control point for
the induction of peripheral tolerance, by promoting Tr differenti-
ation. Thus, whereas mature DCs (mDCs) are potent Ag-
presenting cells enhancing T cell immunity, immature DCs (iDCs)
are involved in the induction of peripheral T cell tolerance under
steady-state conditions (2–6). However, the clinical use of iDCs
may not be suitable for the treatment of autoimmune diseases,
because iDCs are likely to mature in inflammatory conditions (6),
emphasizing the need to develop tolerogenic DCs with a strong
potential to induce Tr. Immunosuppressive therapy, traditionally
focused on lymphocytes, has been revolutionized by targeting the
development and key functions of DC, and the generation of
tolerogenic DCs in the laboratory has become the focus of new
therapies (7).
Vasoactive intestinal peptide (VIP) is a neuropeptide released by
both innervation and immune cells, particularly T helper (Th)2
cells, in response to Ag stimulation and under inflammatory
autoimmune conditions (8). VIP elicits a broad spectrum of bio-
logical functions, including immunomodulation, predominantly act-
ing as a potent antiinflammatory factor and a suppressive agent for
Th1 responses (9). Therefore, VIP has emerged as a promising
therapeutic factor for the treatment of autoimmuneinflammatory
diseases, including rheumatoid arthritis (RA), ulcerative colitis,
uveoretinitis, and experimental autoimmune encephalomyelitis
(EAE) (10–12). In this study, we investigated whether the presence
of VIP during the early phases of DC differentiation induces the
generation of regulatory DCs with the capacity to induce Tr and to
prevent autoimmunity.
Materials and Methods
Cell Isolation and Cultures. Bone marrow (BM)-derived DCs
(BM-DCs) were generated as described in ref. 13. Briefly, BM
cells (2 106) obtained from BALBc (H-2d), C57BL6 (H-2b),
or DBA1 (H-2q) mice were incubated in complete medium
(RPMI medium 1640 supplemented with 100 units/ml penicillin
strectomycin, 2 mM L-glutamine, 50 M 2-mercaptoethanol, and
10% heat-inactivated FCS) containing 20 ngml granulocyte
macrophage colony-stimulating factor in the presence or absence
of VIP (108 M). At day 6, nonadherent cells were collected
(routinely containing 80–90% CD11c cells) and stimulated for
48 h with LPS (1 g/ml) to induce activationmaturation. In
some experiments, DCs were pulsed with ovoalbumin (OVA),
collagen II (CII), or myelin oligodendrocyte glycoprotein
(MOG) (20 gml) for 12 h. Allogeneic naı¨ve CD4 T cells were
purified from C57BL6 mice by positive immunomagnetic se-
lection (MACS, Miltenyi Biotec, Auburn, CA).
Flow Cytometry. Cells were incubated with various peridinin–
chlorophyll–protein complex (PerCP)-, FITC- and phycoerythrin
(PE)-labeled mAbs (BD Pharmingen), diluted at optimal concen-
tration for immunostaining, fixed in 1% paraformaldehyde, and
analyzed on a FACSCalibur flow cytometer (Becton Dickinson).
We used isotype-matched Abs as controls and IgG block (Sigma)
to avoid the nonspecific binding to Fc-receptors.
Cytokine Assays. Cytokine contents in the culture supernatants were
determined by specific sandwich ELISAs by using capturebiotin-
ylated detection Abs from BD Pharmingen. For intracellular anal-
ysis of cytokines in restimulated CD4 T cells, 106 cells per ml were
collected and stimulated with phorbol 12-myristate 13-acetate (1
ngml) plus ionomycin (20 ngml) for 8 h in the presence of
monensin. Cells were stained with PerCP-anti-CD4 mAbs for 30
min at 4°C, washed, fixedsaponin-permeabilized with Cytofix
Cytoperm, stained with 0.5 g per sample FITC- and PE-
conjugated anticytokine-specific mAbs, and analyzed by flow cy-
tometry. To distinguish between DC and T cell sources,
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intracellular cytokine analysis was done exclusively in the PerCP-
labeled CD4 T cell population.
mRNA Analysis. Total RNA was isolated from CD4 T cells, and
real-time PCR was used to determine Foxp3 and neuropilin mRNA
expression, as described in refs. 14 and 15.
Mixed Leukocyte Reaction and Analysis of Tr Cell Function.Naı¨ve CD4
T cells (2  105) were cultured with allogeneic DCcontrol or DCVIP
at various T:DC ratios in the presence of IL-2 (100 unitsml) for 3 d.
Cell proliferation was evaluated by using a cell-proliferation assay
(BrdUrd) from Roche Diagnostics (Mannheim, Germany), and
intracellular cytokine content was determined as described above.
In some experiments, DCs (105) were cultured with purified
allogeneic CD4 T cells (5 105). One week later, CD4 T cells were
recovered by immuodepletion of CD11c DCs and cultured in
different numbers with syngeneic CD4 T cells (5  105) in the
presence of allogeneic mDC (105), and the proliferative response
was determined. Some cultures were performed in the presence of
blocking anti-IL-10 (10 gml) andor anti-TGF1 (40 gml)
mAbs. To determine the cell-contact-dependence of the regulatory
response, we placed responder CD4 T cells (5  105) with LPS-
matured DC (105) in the bottom well of a Transwell system
(Millipore) and syngeneic TrVIP (2  105) with allogeneic mDC
(105) in the upper Transwell chamber. After 72 h, we measured the
proliferative response of the bystander reactive CD4 T cells in the
bottom well. To generate CII- and MOG-specific Tr cells, DBA1J
and C57BL6 DCs (105) pulsed with CII or MOG, respectively,
were cultured with syngeneic CD4 T cells (5 105) for 1week in the
presence of CII or MOG (20 gml).
Immunization Model. BALBc mice were injected s.c. with different
numbers (from 50 to 5 105) of cells of methylated BSA (mBSA)-
pulsed DCcontrol or DCVIP, followed a week later by s.c. immuni-
zation with the Ags mBSA or OVA (60 g) in complete Freund’s
adjuvant. Five days after Ag immunization, serum Ag-specific Ab,
draining lymph nodes (DLN) T cell proliferative responses, and
delayed type hypersensitivity (DTH) responses were measured. For
the DTH responses, mice were injected i.d. with Ag (5g) or saline
into the ears, and ear swelling was measured 24 h later by using a
caliper. Ag-specific T cell proliferative responses were measured
after ex vivo stimulation of DLN cells (4  105) with 10 M Ag.
Levels of mBSA-specific IgG in serum were determined by ELISA,
as described in ref. 16.
Model for RA and EAE. RA was induced in DBA1J mice by s.c.
injection of CII, as described in ref. 10. Chronic EAE was induced
in C57BL6 mice by s.c. immunization with MOG35–55, as described
in ref. 17. Mice with established arthritis (with a clinical score of 2)
were injected i.v. with different numbers of syngeneic CII-pulsed
DCcontrol or DCVIP or with CII-specific Trcontrol or TrVIP. Mice with
established EAE (with a clinical score of 1) were injected i.v. with
different numbers of syngeneic MOG35–55-pulsed DCcontrol or
DCVIP or with MOG35–55-specific Trcontrol or TrVIP. The clinical
score was determined daily, based on joint inflammation for RA
and tailleg paralysis for EAE, as described in ref. 17. DLN cells
were isolated at the peak of the diseases, stimulated with CII or
MOG35–55 (20 gml), and assayed for proliferation and cytokine
production, as described above. The content of serum anti-CII or
anti-MOG35–55 IgG antibodies was determined by ELISA, as
described in refs. 10 and 18. To assess Ag-specificity, arthritic mice
were injected with unpulsed, OVA-pulsed, or CII- or MOG35–55-
pulsed DCcontrol or DCVIP and immunized s.c. with OVA, CII, or
MOG35–55 (150 g of Ag in complete Freund’s adjuvant) one week
later. After 5 d, mice received 5 g of Ag i.d. in the ear pinna, and
the DTH response was determined, as described above. In some
experiments, collagen-induced arthritis (CIA) and EAE mice re-
ceived i.v. injections of neutralizing anti-IL-10 polyclonal Ab,
neutralizing anti-TGF mAb, or preimmune rat IgG used as
control Ig (500g of Ab per mouse) on alternate days up to 8 d after
onset of disease.
Results and Discussion
The induction of Ag-specific tolerance is critical for the prevention
of autoimmunity and maintenance of immune tolerance. In addi-
tion to their classical role as sentinels of the immune response
inducing T cell reactivity, increasing evidence now indicates that
DCs can induce specific T cell tolerance. Although underlying
mechanisms are not fully elucidated, the capacity to induce Tr cells
is an important property of tolerogenicregulatory DCs. The
generation of ‘‘designer’’ DCs with tolerogenic properties in the
laboratory by using specific cytokines or immunologic and phar-
macologic reagents is a desirable goal and represents the subject of
intensive investigations. Because of its immunosuppressive action,
VIP is a candidate for the induction of regulatory DCs with capacity
to generate Tr. In a previous study, we showed that VIP treatment
of activated DCs reduces their capacity to activate allogeneic and
syngeneic T cells, an effect associated with the prevention of
CD80CD86 up-regulation (19). VIP treatment of iDC in the
absence of activation resulted in DCs with increased capacity to
induce Th2 responses (19). However, other immunomodulatory
factors with capacity to induce tolerogenic DCs have been found to
be effective when administered during the differentiation of DCs
(6, 7). Therefore, we determined whether exposure to VIP during
DC differentiation results in DC phenotypic and functional
changes.
BM-DC Differentiated with VIP Induce Regulatory Tr1-Like Cells and
Tolerance in Vivo. We first compared murine BM-derived DCs
generated in the presence or absence of VIP in terms of surface
markers and cytokine production. As previously described, BM
cells cultured with granulocyte macrophage colony-stimulating
factor for 6 d differentiate into iDCs (data not shown). Upon LPS
stimulation, iDCs mature to DCs expressing high levels of DC
markers (CD11c), MHC molecules (class I and class II), and
costimulatory molecules (CD40, CD80, and CD86) (Fig. 1a,
DCcontrol). However, DCs generated in the presence of VIP
(DCVIP) were resistant to the LPS-induced up-regulation of the
costimulatory molecules (CD40, CD80, and CD86) (Fig. 1a). Upon
Fig. 1. VIP induces a stable ‘‘semimature’’ phenotype in BM-DCs. DCs were
generated from mouse BM cells in the absence (DCcontrol) or presence (DCVIP)
of VIP and activated with LPS to induce DC maturation. (a) DCcontrol and DCVIP
were double-labeled for different markers and analyzed by flow cytometry.
Numbers represent the percentage of positive cells (n  4). (b) Cytokine
content in the DC supernatants was determined by ELISA (n  4).









toll-like receptor activation, iDCs mature into cells capable of
producing high levels of inflammatory cytokines. In contrast to
DCcontrol, which produce TNF and IL-12, and low levels of IL-10,
DCVIP produce very low levels of proinflammatory cytokines (TNF
and IL-12) but secrete significant levels of the antiinflammatory
cytokine IL-10 (Fig. 1b). Taken together, these results indicate that
the DCs generated in the presence of VIP are resistant to LPS-
induced up-regulation of costimulatory molecules and produce
IL-10. These characteristics are quite similar to those reported for
tolerogenic DCs generated with other immunomodulatory factors,
such as IL-10 or the activated form of vitamin D 1,25(OH)2D3 (2–4,
20–24).
Tolerogenic DCs are poor stimulators of T cell proliferation and
cytokine production (20, 25–28). To examine the capacity of the
DCVIP to stimulate T cells, we cocultured DCcontrol or DCVIP with
alloreactive CD4 T cells. Priming with DCcontrol results in a strong
proliferation of allogeneic CD4 T cells, whereas DCVIP induce only
weak proliferation (Fig. 2a). In addition, CD4 T cells primed with
DCVIP reexposed to fresh LPS-stimulated allogeneic DCs (mDC)
did not proliferate (data not shown), indicating that DCVIP induces
anergic T cells andor Tr. Although Tr generated by exposure to
regulatorytolerogenic DCs do not proliferate in response to the
Ag, they can release antiinflammatory cytokines, such as IL-10 and
TGF. Therefore, we assessed the cytokine profile of T cells
cocultured with DCVIP. In contrast to T cells exposed to DCcontrol,
which show a predominant Th1 cytokine profile, with high levels of
IFN and IL-2, CD4 T cells primed with allogeneic DCVIP exhibit
a Tr1-like phenotype, characterized by IL-10 and TGF but not
IL-2 and IFN production (Fig. 2b).
After TCR stimulation, Tr cells suppress the proliferation and
IL-2 production of Ag-specific effector T cells. To determine
whether T cells exposed to DCVIP become functional Tr, we
restimulated CD4 T cells with allogeneic mDCs in the presence of
syngeneic CD4 T cells previously exposed to allogeneic DCcontrol
(Trcontrol) or DCVIP (TrVIP). TrVIP inhibit the proliferation of
syngeneic responder CD4 cells in response to allogeneic mDCs in
a dose-dependent manner, whereas Trcontrol are not suppressive
(Fig. 2c). Similar results were obtained in respect to IL-2 production
(data not shown). Therefore, the phenotype of TrVIP correlates with
their regulatory T cell activity.
The observation that TrVIP produce high levels of the immuno-
suppressive cytokines IL-10 and TGF suggests that the inhibitory
Fig. 2. Murine DCs differentiated in the presence of
VIP induce regulatory Tr1 cells and tolerance in vivo.
DCs were generated from mouse BM cells in the ab-
sence (DCcontrol) or presence (DCVIP) of VIP and acti-
vatedwith LPS to induceDCmaturation. (a) DCcontrol or
DCVIPwas added toallogeneic CD4T cells (5105), and
the proliferative responsewas determined. DCcontrol or
DCVIP without T cells did not proliferate. Each result is
the mean  SD of three experiments performed in
duplicate. (b) Purified CD4 T cells were exposed to
allogeneic DCcontrol or DCVIP and activated with phor-
bol 12-myristate 13-acetate plus ionomycin. Intracel-
lular cytokines were determined in CD4-gated cells by
flow cytometry. Numbers represent percentage of
positive cells (n  5). (c) Purified CD4 T cells were
stimulated for 1 week with allogeneic DCcontrol or
DCVIP. The resulting regulatory CD4 T cells (Tr) were
incubatedwith syngeneic responder CD4 T cells (rCD4)
in the presence of allogeneic mDCs, and the prolifer-
ative response was determined (n  4). (d) Isolated
CD4 T cells were cocultured with syngeneic TrVIP and
allogeneic mDCs in the presence or absence of block-
ing anti-IL10 andor anti-TGF. Additionally,
CD4mDCs were separated from TrVIPmDC in a
Transwell system. The proliferative response of re-
sponder CD4 T cells was determined (n 4). (e) Sorted
CD4 T cells generated with DCcontrol or DCVIP were
analyzed for neuropilin 1 and Foxp3mRNA expression
by real-time RT-PCR and for surface CD103 and glu-
cocorticoid-induced TNF receptor (GITR) expression by
flow cytometry. Open histograms and dashed lines
represent isotype controls. One representative exper-
iment of two is shown. ( f) Mice were injected s.c. with
increasing numbers (from 50 to 5  105 cells) of Ag-
pulsed DCcontrol or DCVIP 1 week before priming with
Ag. Five days later, mice were tested for DLN Ag-
specific T cell proliferation, serum antibody levels, and
DTH responses. Mice injected with Ag alone (None)
were used as controls. Results are the mean  SD for
each group (n  4) tested separately and are repre-
sentative of three experiments.
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effect of TrVIP on responder CD4 T cell proliferation might be
mediated through soluble factors produced. When TrVIP and
responder CD4 T cells were separated in transwell experiments by
a semipermeable membrane that allows the free exchange of
soluble factors but excludes direct cell contact of responder CD4 T
cells and TrVIP, the proliferation of effector CD4 cells was still
inhibited, indicating that soluble factors mediate the inhibitory
effect (Fig. 2d). In regular cocultures, the addition of anti-TGF, or
anti-IL-10 Abs reversed inhibition modestly. However, the addition
of both anti-IL-10 and anti-TGFAbs reverses the inhibitory effect
almost completely (Fig. 2d).
Several populations of CD4 Tr have been described and char-
acterized, including the naturally occurring thymic-born
CD4CD25 Tr and the induced peripheral Tr, consisting of
IL-10-producing Tr1 and TGF-secreting Th3Tr2 (29). Regula-
tory DCs do not participate in the generation of naturally occurring
CD4CD25 Tr; however, they play an important role in the
differentiation of peripherally induced Tr1 and Th3Tr2 Tr (30–
32). Although the CD4CD25 population is slightly increased in
TrVIP, the fact that TrVIP did not express significant levels of the
CD4CD25 Tr markers Foxp3, neuropilin-1, glucocorticoid-
induced TNF-receptor-family-related gene, and CD103 (Fig. 2e),
argues against the possibility that DCVIP induce the generation of
CD4CD25 Tr cells. There are no reports on the expression of
neuropilin-1 in IL-10-induced Tr1 cells. However, in contrast to
CD4CD25 Tr, and in agreement with our results, Tr1 cells
generated by repetitive stimulation with IL-10-secreting regulatory
DCs have been shown to express low levels of CD25 and Foxp3 (33).
Although the precise mechanisms remain unknown, several
possibilities may account for the generation of Tr cells by DCVIP.
The activation of naı¨ve CD4 T lymphocytes requires several signals
delivered by mDCs and mediated through AgMHCII–TCR,
CD80CD86–CD28, and CD40–CD40L interactions. Costimula-
tory molecules, especially CD40, appear to be key determinants of
the decision between tolerance and immunity (34). The character-
istic phenotype of DCVIP, i.e., high levels of MHC plus poor
expression of costimulatory molecules, which will deliver stimula-
tory but not costimulatory signals, is in agreement with DCVIP’s
tolerance-inducing ability. In addition, the observation that DCVIP
secrete IL-10 may be linked to the stability of DCVIP’s tolerogenic-
Fig. 3. Therapeutic effect of DC differentiated with VIP in RA and EAE. (a) DBA1J mice (H-2q) with established CIA or C57BL6 mice (H-2b) with established
EAE were treated (arrows) with syngeneic CII-pulsed DCs or MOG-pulsed DCs, respectively, generated in the absence (DCcontrol, E) or presence (DCVIP,  of VIP.
UntreatedCIAandEAEmice (none,F)wereusedas controls. Clinical scorewasmonitored (n12). (b) CII- andMOG-pulsedDCVIPwere injectedat different doses.
(c) CII-induced proliferation and IFN production by spleen T cells, and the levels of anti-CII IgG in sera were determined in CIA mice injected with DCcontrol or
DCVIP (n  5). (d) The effect of DCVIP is Ag-specific. Arthritic mice were treated with unpulsed, CII-pulsed, or OVA-pulsed DCcontrol or DCVIP after disease onset.
One week later, mice were immunized s.c. with OVA or CII and challenged i.d. in the ear pinna with the respective Ag 5 d later. Clinical score and DTH responses
weredetermined24h later (n5). (e)UntreatedCIAor EAEmiceor animals injectedwithDCVIP and treatedwith control Ig, anti-IL10, anti-TGF, or a combination
of both mAbs (10 mice per group).









like phenotype (20, 35–37). Previously, VIP has been reported to
inhibit NF-Bp65 nuclear translocation, DNA-binding, and trans-
activating activity in macrophages (9), and we have recently found
that both NF-Bp65 nuclear translocation and IkB phosphorylation
are inhibited in DCVIP (M.D., E.G.-R., and D.G., unpublished
data). The connection among NF-B transactivating activity, CD40
expression, and DC function (including TNF- and IL-12 produc-
tion) has been established in a number of recent studies. The
association between tolerance, particularly tolerogenic DCs, and
lack of CD40 expression or signaling has been demonstrated both
in vivo and in vitro (28). Expression of CD40 depends on NF-Bp65
(38), and the inhibition of NF-B in DCs leads to failure of CD40,
CD80, and CD86 expression upon LPS-stimulation and to the
generation of tolerogenic DCs (39). In addition, a recent study
suggests that VIP treatment induced a decrease of toll-like recep-
tors (TLR-24) expressions in DCs in a murine model of Crohn’s
disease by a mechanism that would involve a decrease of NF-B
activation (40). Therefore, we would like to propose that the
mechanism by which VIP induces tolerogenic DCs involves the
cAMPPKA-mediated inhibition of IB phosphorylation and NF-
Bp65 nuclear translocation, leading to lack of CD40 expression,
TLR-24 signaling, and inflammatory cytokine production.
Because DCVIP appear to have a predominantly negative effect
on Th1 cells, we determined the effect of DCVIP in an in vivomodel
of DTH. Ag (methylated-BSA)-pulsed DCVIP and DCcontrol were
administered i.v., followed a week later by s.c. antigenic immuni-
zation. We determined T cell proliferation in response to ex vivo
restimulation, Ab production, and DTH after a secondary s.c. Ag
administration (Fig. 2f). Mice that received DCcontrol developed
DTH reactions higher than controls (no DCs), whereas those
receiving DCVIP exhibited reduced DTH. In addition, DLN T cells
from mice inoculated with DCcontrol proliferated at higher levels
than controls (no DCs), and, again, inoculation of DCVIP resulted
in a substantial reduction in T cell proliferation after ex vivo
restimulation with the Ag. Similarly, mice inoculated with DCcontrol
produced high levels of anti-mBSA Abs, whereas those inoculated
with DCVIP had anti-mBSA Ab levels below control (no DCs) (Fig.
2f). These results indicate that DCVIP induce tolerance in vivo. The
induction of tolerance is restricted to the Ag presented by the
inoculated DC, because we did not observe reduction in DTH in
mice injected with mBSA-pulsed DCVIP when we used an unrelated
Ag (OVA) for immunization and ex vivo T cell restimulation (data
not shown). These experiments suggest the possibility of using a
VIP in vitro system to generate Ag-specific tolerogenic DCs,
followed by in vivo administration of these cells to patients with
autoimmune diseases.
Therapeutic Effect of DCVIP in Autoimmunity. Several reports have
recently proposed the possibility of using regulatorytolerogenic
DCs generated ex vivo as a therapeutic tool to prevent organ-
specific autoimmune diseases (3, 7, 21). Interestingly, DCVIP re-
tained their T cell regulatory capacity in vitro and in vivo under
inflammatory conditions. This observation is particularly relevant
for conditions in which ongoing Ag presentation is associated with
chronic inflammation, including autoimmune diseases. Therefore,
we tested the therapeutic effect of DCVIP in two murine models of
RA and multiple sclerosis (MS). For RA, we used the CIA, an
experimental disease model induced by immunization with CII,
which shares a number of clinical, histologic, and immunological
features with RA. For MS, we used the EAE model induced by
MOG35–55 in C57BL6 mice that mirror different clinical charac-
teristics of MS. Inoculation of DCcontrol does not ameliorate arthritis
(i.e., joint inflammation, cartilage destruction, and bone erosion) or
EAE (i.e., tail and leg paralysis) (Fig. 3a). In contrast, administra-
tion of syngeneic DCVIP after the onset of disease abrogates arthritis
and EAE progression in a dose-dependent manner (Fig. 3 a and b).
The therapeutic effect of DCVIP was associated with the down-
regulation of the autoimmune component of both diseases, because
DLN T cells from DCVIP-treated mice showed weak proliferation
and IFN production in response to the autoantigen (Fig. 3c).
Furthermore, this inhibition of the Th1-type autoreactive response
correlates with decreased levels of CII- and MOG-specific auto-
antibodies (Fig. 3c). The effect of DCVIP was Ag-specific. Unpulsed
or OVA-pulsed DCVIP showed a weak therapeutic effect on ar-
thritis, while reducing OVA-specific, but not CII-specific, DTH
responses. In contrast, CII-pulsed DCVIP inhibit arthritis and DTH
response toward CII but not toward OVA (Fig. 3d). Similar
Ag-dependence was observed in the EAE model (data not shown).
These results indicate that DCVIP generated ex vivo could prevent
organ-specific autoimmune disorders in matched subjects, probably
by inducing Ag-specific Tr cells, which suppress the ongoing auto-
reactiveinflammatory response. The participation of Tr cells in the
therapeutic effect of DCVIP correlated with the fact that DCVIP
induce in vitro the generation of IL-10TGF-producing regulatory
CD4 T cells (Fig. 2). Therefore, we further examined the role of Tr
in the therapeutic effect of DCVIP on both CIA and EAE. In vivo
blockade experiments showed that treatment with anti-IL-10 or
anti-TGF Abs significantly decrease disease amelioration, and
treatment with both Abs abrogates the beneficial effects exerted by
DCVIP (Fig. 3e), suggesting the partial involvement of newly gen-
erated Tr cells in such action.
DCVIP-Induced Tr Ameliorate Autoimmunity. In certain circum-
stances, successful suppression of an autoimmune response
might require high numbers of Tr, and the in vivo administration
of DCVIP might not be sufficient for a complete and rapid
suppression. Therefore, we decided to generate in vitro Ag-
specific DCVIP-induced Tr cells and to subsequently determine
their suppressive capacity in vivo in both the CIA and EAE
models. We generated CII- or MOG-specific TrVIP through
stimulations of CD4 T cells with syngeneic CII- or MOG-pulsed
DCVIP. Trcontrol were generated in the same manner with
DCcontrol. Treatment with TrVIP, but not Trcontrol, of mice with
established CIA or EAE prevented disease progression in a
dose-dependent manner (Fig. 4a). This effect was mainly me-
diated through TGF and IL-10, because in vivo administration
Fig. 4. DCVIP-induced Tr prevent autoimmunity. (a) Therapeutic effect on
arthritis. CIA (H-2q) or EAE mice (H-2b) with established disease were treated
with syngeneic CII- andMOG-specific Trcontrol (E) orwith different doses of CII-
or MOG-specific TrVIP (106 cells, ; 5 105 cells, ƒ; 5 104 cells, ■). Untreated
mice (F)were used as CIA andEAE controls. Clinical scorewas determined (n
10). (b) Untreated CIAEAE mice or CIAEAE mice injected with TrVIP and
treated with control Ig, anti-IL10, anti-TGF, or anti-IL10 plus anti-TGF Abs.
Clinical score was measured at the peak of the disease (n  10).
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of anti-IL10 andor anti-TGF Abs abrogated the protective
effect (Fig. 4b). In both models, the protective effect of TrVIP was
Ag-specific, because OVA-specific TrVIP did not efficiently
ameliorate arthritis or paralysis (data not shown). These results
indicate that Ag-specific Tr1-like cells generated in vitro with
DCVIP can efficiently modulate pathogenic immune responses
in vivo.
VIP has been previously found to ameliorate CIA and EAE,
mainly by down-regulating the two components of both diseases,
inflammation and Th1-mediated autoimmunity (ref. 10 and
E.G.-R., A.F.-M., A.C., D.P., D.G., and M.D., unpublished
results). The involvement of Tr cells in the therapeutic effect of
VIP was demonstrated by the fact that CD4 T cells isolated by
VIP-treated CIA or EAE mice showed an increased regulatory
suppressive activity against self-reactive Th1 cells. Phenotypic
analysis of these Tr cells indicated that they consist of a mix of
Foxp3CD4CD25 and IL-10Tr1-like cells (E.G.-R., A.C.,
A.F.-M., D.G., and M.D., unpublished results). In addition, by
using a transgenic TCR murine model, we found that VIP
induces the in vivo generation of Ag-specific tolerogenic IL-10-
producing DCs with capacity to generateactivate Tr1-like cells
(M.D., E.G.-R., and D.G., unpublished results). These findings
validate the data obtained in this study, demonstrating that the
pharmacological use of VIP in the treatment of autoimmunity is
exerted partially through the induction of tolerogenic DCs and
Tr1-like cells.
It has been proposed that tolerance induction by DCs requires
maturation signals different from microbial or inflammatory
stimuli. In steady-state conditions, VIP could represent one of
the endogenous maturation signals driving the differentiation of
tolerogenic DCs with a regulatory phenotype. VIP is secreted in
the lymphoid microenvironment, mainly by Th2 cells, after Ag
stimulation, and VIP levels are increased in immunopathologic
conditions, such as autoimmunity and inflammation (8, 9).
Therefore, DCVIP may represent a population of DCs that have
matured to display a stable tolerogenic phenotype. Under
steady-state conditions, DCVIP could be loaded with self- and
commonly encountered Ags, and, after migration to the lym-
phoid organs, they could induce Tr1 differentiation and toler-
ance. Interestingly, in subjects with various autoimmune disor-
ders, reduced serum VIP levels and increased VIP-specific
autoantibodies have been reported (41).
Numerous strategies based on immunosuppressive agents,
such as vitamin-D3, IL-10, TGF, glucocorticoids, and N-acetyl-
L-cysteine, alone or in combinations, have been used to induce
tolerogenic DCs (7). However, in the case of regulatory DCs
induced with vitamin D analogs, it looks as if these regulatory
DCs induce CD4CD25 Tr cells rather than Tr1-like cells (7).
Our data demonstrate that VIP is very efficient at the induction
of regulatory DCs, in comparison with current strategies, and we
propose that the addition of VIP to cocktails of immunomodu-
latory agents will increase their effectiveness.
In conclusion, the possibility of generating tolerogenic DCVIP
opens therapeutic perspectives for the treatment of autoim-
muneinflammatory diseases and in allogeneic transplantation.
In vitro pulsing of tolerogenic DCVIP with self-Ags, followed by
in vivo injection, leads to the differentiation of Ag-specific Tr
cells. Therefore, the inclusion of tolerogenic DCVIP in future
therapeutic regimens may minimize the dependence on nonspe-
cific immunosuppressive drugs used currently for autoimmune
disorders.
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